REPLY: My coauthors and I read with interest the letter from Dr. Papantoniou et al. Much of the letter reports on the use of 99mTc-(V)DMSA for imaging of breast lesions. We did not use this tracer in our study and have only little experience with it. The authors agree with us that a faint and diffuse sestamibi uptake must not be considered as nonspecific or probably benign. The idea of a scoring system for scintimammography is interesting and must be validated. In our study, invasive—not only in situ—lobular carcinoma was associated with a faintly diffuse and heterogeneous uptake of sestamibi. Therefore, we think that the proposed class 3 should not refer only to a preinvasive component. Differentiating in situ from invasive components within a heterogeneous area of tracer uptake is probably not possible because of the limited spatial resolution of SPECT. After initial validation, such a scoring system could be tested in a prospective, preferably multicentric, clinical setting. A robust scoring system would certainly increase the strength of scintimammography as a second-line breast imaging technique.